Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm

Sosei Kuma, Koichi Morisaki, Akio Kodama, Atsushi Guntani, Ryota Fukunaga, Yoshimitsu Soga, Shinichi Shirai, Masaru Ishida, Jin Okazaki, Shinsuke Mii

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of postcatheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan. Methods and Results: A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of postcatheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100–600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91%, 0% and 4% in the femoral PSA, and 89%, 11% and 11% in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months. Conclusions: UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.

Original languageEnglish
Pages (from-to)1277-1281
Number of pages5
JournalCirculation Journal
Volume79
Issue number6
DOIs
Publication statusPublished - May 11 2015

Fingerprint

False Aneurysm
Thrombin
Catheterization
Injections
Arm
Thigh
Recurrence
Brachial Artery
Femoral Artery
Japan
Outpatients
Therapeutics
Retrospective Studies
Smoking
History
Demography

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm. / Kuma, Sosei; Morisaki, Koichi; Kodama, Akio; Guntani, Atsushi; Fukunaga, Ryota; Soga, Yoshimitsu; Shirai, Shinichi; Ishida, Masaru; Okazaki, Jin; Mii, Shinsuke.

In: Circulation Journal, Vol. 79, No. 6, 11.05.2015, p. 1277-1281.

Research output: Contribution to journalArticle

Kuma, S, Morisaki, K, Kodama, A, Guntani, A, Fukunaga, R, Soga, Y, Shirai, S, Ishida, M, Okazaki, J & Mii, S 2015, 'Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm', Circulation Journal, vol. 79, no. 6, pp. 1277-1281. https://doi.org/10.1253/circj.CJ-14-1119
Kuma, Sosei ; Morisaki, Koichi ; Kodama, Akio ; Guntani, Atsushi ; Fukunaga, Ryota ; Soga, Yoshimitsu ; Shirai, Shinichi ; Ishida, Masaru ; Okazaki, Jin ; Mii, Shinsuke. / Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm. In: Circulation Journal. 2015 ; Vol. 79, No. 6. pp. 1277-1281.
@article{24b3bbb7a719496cbe522fd4df4904eb,
title = "Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm",
abstract = "Background: The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of postcatheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan. Methods and Results: A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of postcatheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100–600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91{\%}, 0{\%} and 4{\%} in the femoral PSA, and 89{\%}, 11{\%} and 11{\%} in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months. Conclusions: UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.",
author = "Sosei Kuma and Koichi Morisaki and Akio Kodama and Atsushi Guntani and Ryota Fukunaga and Yoshimitsu Soga and Shinichi Shirai and Masaru Ishida and Jin Okazaki and Shinsuke Mii",
year = "2015",
month = "5",
day = "11",
doi = "10.1253/circj.CJ-14-1119",
language = "English",
volume = "79",
pages = "1277--1281",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm

AU - Kuma, Sosei

AU - Morisaki, Koichi

AU - Kodama, Akio

AU - Guntani, Atsushi

AU - Fukunaga, Ryota

AU - Soga, Yoshimitsu

AU - Shirai, Shinichi

AU - Ishida, Masaru

AU - Okazaki, Jin

AU - Mii, Shinsuke

PY - 2015/5/11

Y1 - 2015/5/11

N2 - Background: The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of postcatheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan. Methods and Results: A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of postcatheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100–600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91%, 0% and 4% in the femoral PSA, and 89%, 11% and 11% in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months. Conclusions: UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.

AB - Background: The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of postcatheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan. Methods and Results: A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of postcatheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100–600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91%, 0% and 4% in the femoral PSA, and 89%, 11% and 11% in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months. Conclusions: UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.

UR - http://www.scopus.com/inward/record.url?scp=84930074380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930074380&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-14-1119

DO - 10.1253/circj.CJ-14-1119

M3 - Article

C2 - 25797019

AN - SCOPUS:84930074380

VL - 79

SP - 1277

EP - 1281

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -